A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study

Vincenzo Spagnuolo; Laura Galli; Andrea Poli; Alba Bigoloni; Luca Fumagalli; Nicola Gianotti; Silvia Nozza; Davide Ferrari; Massimo Locatelli; Adriano Lazzarin; Antonella Castagna

doi:10.2147/DDDT.S192124

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study

Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Alba Bigoloni, Luca Fumagalli, Nicola Gianotti, Silvia Nozza, Davide Ferrari, Massimo Locatelli, Adriano Lazzarin, Antonella Castagna

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	477-479
Number of pages	3
Journal	Drug Design, Development and Therapy
Volume	13
DOIs	https://doi.org/10.2147/DDDT.S192124
Publication status	Published - Jan 1 2019

ASJC Scopus subject areas

Pharmacology
Pharmaceutical Science
Drug Discovery

Access to Document

10.2147/DDDT.S192124

Cite this

Spagnuolo, V., Galli, L., Poli, A., Bigoloni, A., Fumagalli, L., Gianotti, N., Nozza, S., Ferrari, D., Locatelli, M., Lazzarin, A., & Castagna, A. (2019). A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study. Drug Design, Development and Therapy, 13, 477-479. https://doi.org/10.2147/DDDT.S192124

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure : The DOLATAV study. / Spagnuolo, Vincenzo ; Galli, Laura ; Poli, Andrea ; Bigoloni, Alba; Fumagalli, Luca; Gianotti, Nicola ; Nozza, Silvia; Ferrari, Davide; Locatelli, Massimo; Lazzarin, Adriano; Castagna, Antonella.

In: Drug Design, Development and Therapy, Vol. 13, 01.01.2019, p. 477-479.

Research output: Contribution to journal › Letter › peer-review

Spagnuolo, V , Galli, L , Poli, A , Bigoloni, A, Fumagalli, L, Gianotti, N , Nozza, S, Ferrari, D, Locatelli, M, Lazzarin, A & Castagna, A 2019, 'A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study', Drug Design, Development and Therapy, vol. 13, pp. 477-479. https://doi.org/10.2147/DDDT.S192124

Spagnuolo, Vincenzo ; Galli, Laura ; Poli, Andrea ; Bigoloni, Alba ; Fumagalli, Luca ; Gianotti, Nicola ; Nozza, Silvia ; Ferrari, Davide ; Locatelli, Massimo ; Lazzarin, Adriano ; Castagna, Antonella. / A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure : The DOLATAV study. In: Drug Design, Development and Therapy. 2019 ; Vol. 13. pp. 477-479.

@article{be9c7b5daed944be89e6411b4d6e817c,

title = "A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study",

author = "Vincenzo Spagnuolo and Laura Galli and Andrea Poli and Alba Bigoloni and Luca Fumagalli and Nicola Gianotti and Silvia Nozza and Davide Ferrari and Massimo Locatelli and Adriano Lazzarin and Antonella Castagna",

year = "2019",

month = jan,

day = "1",

doi = "10.2147/DDDT.S192124",

language = "English",

volume = "13",

pages = "477--479",

journal = "Drug Design, Development and Therapy",

issn = "1177-8881",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure

T2 - The DOLATAV study

AU - Spagnuolo, Vincenzo

AU - Galli, Laura

AU - Poli, Andrea

AU - Bigoloni, Alba

AU - Fumagalli, Luca

AU - Gianotti, Nicola

AU - Nozza, Silvia

AU - Ferrari, Davide

AU - Locatelli, Massimo

AU - Lazzarin, Adriano

AU - Castagna, Antonella

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85062060586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062060586&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S192124

DO - 10.2147/DDDT.S192124

M3 - Letter

C2 - 30774311

AN - SCOPUS:85062060586

VL - 13

SP - 477

EP - 479

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this